Crossmark

Improvement of neurological and ocular symptoms of Behçet’s disease after the introduction of infliximab

Crossref DOI link: https://doi.org/10.1007/s00296-018-4054-9

Published Online: 2018-05-17

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Barešić, Marko https://orcid.org/0000-0001-6281-5705
Reihl, Mirna https://orcid.org/0000-0003-3074-1646
Habek, Mario https://orcid.org/0000-0002-3360-1748
Vukojević, Nenad https://orcid.org/0000-0001-7561-8858
Anić, Branimir
License Information

Text and Data Mining valid from 2018-05-17
More Information

Article History

Received: 20 April 2018

Accepted: 14 May 2018

First Online: 17 May 2018

Compliance with ethical standards

:

: The authors have no conflicts of interest to declare.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.